Advances in paediatric pharmacokinetics

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 1, 2011, Pages 1-8

  Knibbe, Catherijne Aj ^a,b   Krekels, Elke Hj ^a   Danhof, Meindert ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Maturation; Paediatrics; Pharmacokinetics; Population PK modelling

Indexed keywords

ARTICLE; DRUG ELIMINATION; DRUG INDUSTRY; DRUG INFORMATION; DRUG RESEARCH; HUMAN; PEDIATRICS; PHARMACOKINETICS; PROCESS DEVELOPMENT; PROSPECTIVE STUDY; VALIDATION STUDY;

ALGORITHMS; CHILD; CLINICAL TRIALS AS TOPIC; EXPERT TESTIMONY; HUMANS; MODELS, BIOLOGICAL; PEDIATRICS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RESEARCH DESIGN;

EID: 78650445238     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2011.539201     Document Type: Article

References (53)

1. Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr 2005;164(9):552-8
2. Website of the Open TCI Iniatitive by the World Society of Intravenous Anaesthesia. Available from: www. opentci.org [Last accessed 1 September 2010]
3. Ince I, de Wildt SN, Tibboel D, et al. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling. Drug Discov Today 2009;14(5-6):316-20
4. Website of the Dutch Top Institute Pharma. Available from: www.tipharma. com [Last accessed 1 September 2010]
5. De Cock RF, Piana C, Krekels EH, et al. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 2010: published online 26 March 2010, doi:10.1007/s00228-009-0782-9
6. Meibohm B, Laer S, Panetta JC, Barrett JS. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 2005;7(2):E475-87
7. Bazzoli C, Retout S, Mentre F. Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0. Comput Methods Programs Biomed 2010;98(1):55-65
8. Website for the winPOPT and POPT sofrware. Available from: www.winpopt. com [Last accessed 1 September 2010]
9. Website for the PopED software. Available from: poped.sourceforge.net [Last accessed 1 September 2010]
10. Website for the PopDes software from the University of Manchester. Available from: www.pharmacy. manchester.ac.uk/capkr/popdes [Last accessed 1 September 2010]
11. McDade EJ, Wagner JL, Moffett BS, Palazzi DL. Once-daily gentamicin dosing in pediatric patients without cystic fibrosis. Pharmacotherapy 2010;30(3):248-53
12. Inparajah M, Wong C, Sibbald C, et al. Once-daily gentamicin dosing in children with febrile neutropenia resulting from antineoplastic therapy. Pharmacotherapy 2010;30(1):43-51
13. Lopez SA, Mulla H, Durward A, Tibby SM. Extended-interval gentamicin: population pharmacokinetics in pediatric critical illness. Pediatr Crit Care Med 2010;11(2):267-74
14. Sherwin CM, Svahn S, Van der LA, et al. Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol 2009;65(7):705-13
15. Knibbe CA, Krekels EH, van den Anker JN, et al. Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet 2009;48(6):371-85
16. Anand KJ, Anderson BJ, Holford NH, et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br J Anaesth 2008;101(5):680-9
17. Allegaert K, de Hoon J, Verbesselt R, et al. Maturational pharmacokinetics of single intravenous bolus of propofol. Paediatr Anaesth 2007;17(11):1028-34
18. De Wildt SN, Kearns GL, Murry DJ, et al. Ontogeny of midazolam glucuronidation in preterm infants. Eur J Clin Pharmacol 2010;66(2):165-70
19. Muchohi SN, Kokwaro GO, Ogutu BR, et al. Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions. Br J Clin Pharmacol 2008;66(4):529-38
20. Prins SA, van Dijk M, Van Leeuwen P, et al. Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. Paediatr Anaesth 2008;18(7):582-92
21. Palmer GM, Atkins M, Anderson BJ, et al. I.V. acetaminophen pharmacokinetics in neonates after multiple doses. Br J Anaesth 2008;101(4):523-30
22. Bressolle F, Rochette A, Khier S, et al. Population pharmacokinetics of the two enantiomers of tramadol and O-demethyl tramadol after surgery in children. Br J Anaesth 2009;102(3):390-9
23. Allegaert K, van Schaik RH, Vermeersch S, et al. Postmenstrual age and CYP2D6 polymorphisms determine tramadol o-demethylation in critically ill neonates and infants. Pediatr Res 2008;63(6):674-9
24. Website for the Simcyp software. Available from: www.simcyp.com [Last accessed 4 November 2010]
25. Website for the PK-Sim software. Available from: www.systems-biology. com/products/pk-sim.html [Last accessed 4 November 2010]
26. Johnson TN, Rostami-Hodjegan A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr anaesth 2010: published online 18 May 2010 DOI: 10.1111/j.1460-9592.2010.03323.x
27. Johnson TN, Rostami-Hodjegan A, Tucker GT. Clin Pharmacokinet 2006;45(9):931-56
28. Peeters MY, Prins SA, Knibbe CA, et al. Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. Anesthesiology 2006;104(3):466-74
29. Nedelman JR. On some "disadvantages" of the population approach. AAPS J 2005;7(2):E374-82
30. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009;24(1):25-36
31. Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 2008;47(4):231-43
32. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther 2007;82(1):17-20
33. Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 2009;11(3):558-69
34. Holford N. The visual predictive check-superiority to standard diagnostic (Rorschach) plots. PAGE 14 Abstract 738. 2005, Available from: www.page-meeting.org/default.asp?abstract=738 [Last accessed 1 September 2010]
35. Brendel K, Comets E, Laffont C, et al. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 2006;23(9):2036-49
36. Khachman D, Laffont CM, Concordet D. You have problems to interpret VPC? Try VIPER. PAGE 19 Abstract 1892. 2010, Available from: http://www.page-meeting. org/default.asp?abstract=1892 [Last accessed 4 November 2010]
37. Dodds PS, Rothman DH, Weitz JS. Re-examination of the "3/4-law" of metabolism. J Theor Biol 2001;209(1):9-27
38. Agutter PS, Wheatley DN. Metabolic scaling: consensus or controversy? Theor Biol Med Model 2004;16:1-13
39. Bokma F. Evidence against universal metabolic allometry. Funct Ecol 2004;18:184-7
40. Glazier DS. Beyond the '3/4-power law': variation in the intra-and interspecific scaling of metabolic rate in animals. Biol Rev 2005;80(4):611-62
41. White CR, Cassey P, Blackburn TM. Allometric exponents do not support a universal metabolic allometry. Ecology 2007;88(2):315-23
42. Mahmood I. Theoretical versus empirical allometry: facts behind theories and application to pharmacokinetics. J Pharm Sci 2010;99(7):2927-33
43. Mahmood I. Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept. Drug Metabol Drug Interact 2009;24(1):57-81
44. Mahmood I. Prediction of drug clearance in children: impact of allometric exponents, body weight, and age. Ther Drug Monit 2007;29(3):271-8
45. Mahmood I. Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol 2006;61(5):545-57
46. Johnson TN. The problem in scaling adult drug doses to children. Arch Dis Child 2008;93(3):190-1
47. Mahmood I. Evaluation of a morphine maturation model for the prediction of morphine clearance in children: how accurate is the predictive performance of the model? Br J Clin Pharmacol. Accepted 2010 DOI: 10.1111/j.1365-2125.2010. 03802.x
48. Peeters MY, Allegaert K, Blusse van Oud-Alblas HJ, et al. Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin Pharmacokinet 2010;49(4):269-75
49. Wang C, Peeters MYM, Allegaert K, et al. Scaling clearance of propofol from preterm neonates to adults using an allometric model with a bodyweight-dependent maturational exponent. PAGE 19 Abstract 1818 2010, Available from: www.page-meeting.org/default.asp?abstract=1818 [Last accessed 1 September 2010]
50. Ince I, De Wildt SN, Peeters MYM, et al. Critical illness is a major determinant for midazolam and metabolite clearance in children. PAGE 19 Abstract 1819, Available from: www.page-meeting.org/default.asp?abstract=1819 [Last accessed 1 September 2010]
51. Anderson BJ, Larsson P. A maturation model for midazolam clearance. Paediatr Anaesth 2010: published online 23 July 2010, doi: 10.1111/j.1460-9592. 2010.03364.x
52. Danhof M, de Jongh J, de Lange EC, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 2007;47:357-400
53. Sharfstein JM, North M, Serwint JR. Over the counter but no longer under the radar-pediatric cough and cold medications. N Engl J Med 2007;357(23):2321-4